GE Healthcare Technologies Inc (GEHC) AI Stock Analysis

• Market Cap: $37.64B
• Dividend Yield: 0.17%
• Average Volume (3M): 2.80M
• Price to Earnings (P/E): 17.3
• Beta (1Y): 1.28
• Revenue Growth: 3.52%
• EPS Growth: 32.21%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.44
• Shares Outstanding: 455,521,600
• 10 Day Avg. Volume: 3,350,515
• 30 Day Avg. Volume: 2,798,397
• PEG Ratio: -1.41
• Price to Book (P/B): 3.61
• Price to Sales (P/S): 1.91
• P/FCF Ratio: -77.68
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 2.20
• Enterprise Value/Gross Profit: 5.05
• Enterprise Value/Ebitda: 12.03
• 1Y Price Target: $93.17
• Price Target Upside: 12.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $88.00 ▲(6.50% Upside)

The score is driven primarily by mixed financial performance—especially the 2025 cash flow deterioration—offset by a stronger balance sheet and supportive 2026 guidance for growth, margins, and free cash flow. Technicals are neutral with negative MACD, and valuation appears reasonable but not notably attractive given the low dividend yield.

Positive Factors

Balance Sheet Strength

Leverage improvement is durable: materially lower debt and a meaningful equity base increase financial flexibility for R&D, M&A and tariff mitigation. A cleaner cap structure reduces interest burden and supports capital allocation through cycles, enhancing long‑term resilience.

Backlog and Enterprise Contracts

A record $21.8B backlog and book-to-bill above 1.0 provide multi-quarter revenue visibility and underpin predictable install/service streams. Large enterprise deals and growing service revenues expand recurring cash flows, reducing cycle sensitivity and supporting durable revenue conversion.

Product Pipeline & Regulatory Progress

A deep, regulated product pipeline with recent clearances and regional launches strengthens differentiation in imaging and radiopharma. Sustained NPI commercialization supports midterm revenue growth, improves product mix, and can lift margins as newer, higher‑value systems scale globally.

Negative Factors

Cash-Flow Deterioration

A sudden collapse in cash conversion creates a durable execution risk: negative FCF constrains reinvestment, limits discretionary capital returns, and increases reliance on financing. Restoring reliable cash generation is critical to fund innovation and acquisitions without raising leverage again.

Tariff Exposure & Operational Complexity

Material tariff costs directly pressure margins and drove significant FY earnings impact. Mitigation (line transfers, contract manufacturers) reduces tariff risk but raises supply‑chain complexity and execution cost, creating ongoing margin volatility until structural solutions are implemented.

China Weakness and Lumpy Orders

A planned China downturn and modest orders growth (quarterly orders were +2%) create demand concentration and timing risk. Reliance on large enterprise bookings and regulatory approvals can make revenue lumpy, complicating forecasting and pressuring near‑term utilization and margin recovery.

GE Healthcare Technologies Inc Business Overview & Revenue Model

Company Description

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

How the Company Makes Money

GE Healthcare generates revenue through several key streams, primarily from the sale of medical imaging equipment, monitoring devices, and software solutions. The company also earns income from service contracts related to the maintenance and support of its products, as well as consumables and accessories that accompany its medical devices. Additionally, GEHC has established significant partnerships with healthcare providers, research institutions, and technology firms, which contribute to its revenue through collaborative projects and the development of innovative healthcare solutions. The ongoing demand for advanced medical technologies, particularly in emerging markets and during healthcare transformations, also plays a crucial role in driving GEHC's earnings.

GE Healthcare Technologies Inc Financial Statement Overview

Summary

Strong balance-sheet improvement with sharply reduced debt and higher equity supports financial stability, but 2025 fundamentals are mixed: revenue turned negative, margins softened, and cash flow is the key concern (reported zero operating cash flow and negative free cash flow), creating near-term execution risk despite prior-year strength.

Income Statement

Revenue has been broadly stable over the last several years (~$17.2B in 2020 to ~$19.6B in 2025), but growth has slowed and turned negative in 2025 (-3.186%). Profitability is generally solid with gross margin improving to ~43.5% in 2025, though operating and net profitability weakened versus 2024 (net margin down from ~10.1% to ~8.6%). Overall, the income statement reflects a steady, profitable business with a recent deceleration and some margin pressure.

Balance Sheet

Leverage has improved dramatically, with total debt dropping from ~9.9B in 2023/ ~9.4B in 2024 to ~0.5B in 2025, bringing debt-to-equity down to ~0.05. Equity also increased meaningfully in 2025 (~$10.4B), supporting a stronger capital position. A key watch item is that returns on equity eased in 2025 (~16.2%) versus 2024 (~23.6%), reflecting lower earnings power despite the cleaner balance sheet.

Cash Flow

Cash generation shows a sharp deterioration in 2025: operating cash flow is reported at 0 and free cash flow is negative (-$482M), versus positive operating cash flow (~$2.0–$2.1B) and healthy free cash flow (~$1.6–$1.8B) in 2022–2024. As a result, cash conversion from earnings fell materially in 2025 (free cash flow relative to net income at 0.0). While prior years indicate solid cash productivity, the latest period introduces meaningful uncertainty and execution risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	19.60B	19.67B	19.55B	18.34B	17.59B
Gross Profit	8.53B	8.21B	7.92B	7.18B	7.17B
EBITDA	3.58B	3.67B	3.51B	3.17B	3.54B
Net Income	1.68B	1.99B	1.57B	1.92B	2.25B
Balance Sheet
Total Assets	36.91B	33.09B	32.45B	27.54B	26.31B
Cash, Cash Equivalents and Short-Term Investments	4.51B	2.89B	2.50B	1.45B	556.00M
Total Debt	508.00M	9.38B	9.86B	8.63B	437.00M
Total Liabilities	26.31B	24.44B	25.14B	17.95B	9.41B
Stockholders Equity	10.38B	8.45B	7.13B	9.36B	16.66B
Cash Flow
Free Cash Flow	-482.00M	1.55B	1.71B	1.80B	1.36B
Operating Cash Flow	0.00	1.95B	2.10B	2.11B	1.61B
Investing Cash Flow	-1.05B	-914.00M	-558.00M	-398.00M	-1.76B
Financing Cash Flow	617.00M	-573.00M	-478.00M	-822.00M	-263.00M

GE Healthcare Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 82.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Positive. The current price of 82.63 is above the 20-day moving average (MA) of 82.15, above the 50-day MA of 82.42, and above the 200-day MA of 75.55, indicating a bullish trend. The MACD of -0.78 indicates Positive momentum. The RSI at 53.33 is Neutral, neither overbought nor oversold. The STOCH value of 42.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GEHC.

GE Healthcare Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HQY	74 Outperform	$6.95B	37.28	9.01%	―	12.20%	98.75%
VEEV	73 Outperform	$31.35B	37.05	13.72%	―	15.96%	27.91%
DOCS	73 Outperform	$6.64B	28.12	24.61%	―	20.21%	44.14%
GEHC	64 Neutral	$37.64B	17.31	24.22%	0.17%	3.52%	32.21%
HNGE	64 Neutral	$2.62B	-6.06	―	―	50.67%	-578.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TEM	51 Neutral	$9.53B	-45.24	-72.61%	―	72.58%	76.81%

GE Healthcare Technologies Inc Corporate Events

GE Healthcare Issues $1.25 Billion in Senior Notes

On December 12, 2025, GE Healthcare Technologies Inc. entered into a three-year senior unsecured term loan credit facility for $750 million, with JPMorgan Chase Bank as the administrative agent. This agreement includes various covenants and is aimed at supporting the company’s financial operations. Additionally, on December 15, 2025, GE Healthcare issued $1.25 billion in senior notes to finance its acquisition of Intelerad Medical Systems, marking a strategic expansion in its healthcare solutions portfolio. The notes are set to mature in 2028 and 2035, respectively, and are part of the company’s broader financial strategy to enhance its market positioning.

The most recent analyst rating on (GEHC) stock is a Hold with a $88.00 price target. To see the full list of analyst forecasts on GE Healthcare Technologies Inc stock, see the GEHC Stock Forecast page.

GE Healthcare Announces $1.25 Billion Notes Offering

On December 1, 2025, GE Healthcare Technologies Inc. announced the commencement and pricing of an underwritten offering of $1.25 billion in aggregate principal amount of notes, with $600 million due in 2028 and $650 million due in 2035. This financial move, involving major underwriters like Goldman Sachs and BNP Paribas, is expected to impact the company’s financial strategy and market positioning, with the notes anticipated to be issued around December 15, 2025, pending customary closing conditions.

The most recent analyst rating on (GEHC) stock is a Hold with a $82.00 price target. To see the full list of analyst forecasts on GE Healthcare Technologies Inc stock, see the GEHC Stock Forecast page.